Key result
Short-term triple antithrombotic therapy (≤6 weeks) was associated with decreased rates of major adverse cardiovascular events, mortality, and bleeding compared to long-term therapy.
Why the study?
In patients receiving coronary stents who have an indication for oral anticoagulation in addition to DAPT, the optimal duration of triple antithrombotic therapy remains uncertain.
Does short-term triple antithrombotic therapy improve efficacy and safety outcomes compared to long-term therapy in patients with coronary stents requiring oral anticoagulation?
Meta-Analysis (n=1,883)
Does short-term triple antithrombotic therapy improve efficacy and safety outcomes compared to long-term therapy in patients with coronary stents requiring oral anticoagulation?
Short-term triple antithrombotic therapy (≤6 weeks) is associated with reduced mortality, major adverse cardiovascular events, and bleeding compared to long-term therapy (6-12 months) in patients with coronary stents requiring oral anticoagulation.
Short TAT may be default for most patients needing OAC post-stent; confirms bleeding reduction without excess ischemia in meta-analyses of RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2019) conducted a meta-analysis in Coronary stents requiring oral anticoagulation (n=1,883). Short-term triple antithrombotic therapy (TAT) vs. Long-term TAT (6-12 months) was evaluated on Major adverse cardiovascular events, cardiac mortality, all-cause mortality, and any-bleeding events. Short-term triple antithrombotic therapy (≤6 weeks) was associated with decreased rates of major adverse cardiovascular events, mortality, and bleeding compared to long-term therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: